Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america

Cryptococcosis is a global invasive mycosis associated with significant morbidity and mortality. These guidelines for its management have been built on the previous Infectious Diseases Society of America guidelines from 2000 and include new sections. There is a discussion of the management of cryptococcal meningoencephalitis in 3 risk groups: (1) human immunodeficiency virus (HIV)-infected individuals, (2) organ transplant recipients, and (3) non-HIV-infected and nontransplant hosts. There are specific recommendations for other unique risk populations, such as children, pregnant women, persons in resource-limited environments, and those with Cryptococcus gattii infection. Recommendations for management also include other sites of infection, including strategies for pulmonary cryptococcosis. Emphasis has been placed on potential complications in management of cryptococcal infection, including increased intracranial pressure, immune reconstitution inflammatory syndrome (IRIS), drug resistance, and cryptococcomas. Three key management principles have been articulated: (1) induction therapy for meningoencephalitis using fungicidal regimens, such as a polyene and flucytosine, followed by suppressive regimens using fluconazole; (2) importance of early recognition and treatment of increased intracranial pressure and/or IRIS; and (3) the use of lipid formulations of amphotericin B regimens in patients with renal impairment. Cryptococcosis remains a challenging management issue, with little new drug development or recent definitive studies. However, if the diagnosis is made early, if clinicians adhere to the basic principles of these guidelines, and if the underlying disease is controlled, then cryptococcosis can be managed successfully in the vast majority of patients.

Conflict of interest statement

Potential conflicts of interest. J.R.G. has served as a research consultant for Schering-Plough. P.G.P. has received grant support from Schering-Plough, Pfizer, Merck, and Astellas; has served as an ad hoc consultant to Pfizer; and has served as a speaker to Pfizer and Astellas. J.R.P. has received grant support from Merck, Astellas, Pfizer, Schering-Plough, and Enzon; has received honoraria from Merck, Astellas, Pfizer, Schering-Plough, and Enzon; and has served as a consultant to Merck, Astellas, Pfizer, Schering-Plough, and Enzon. T.C.S. has received grant support from Pfizer, Merck, and Gilead and has served on advisory boards for Pfizer, Merck, Gilead, and Schering-Plough. O.L. serves on speaker bureaus for Merck, Schering-Plough, Pfizer, and Gilead Sciences. All other authors: no conflicts.

Comment in

Garg M. Garg M. Ann Emerg Med. 2011 Jan;57(1):62-3. doi: 10.1016/j.annemergmed.2010.11.003. Ann Emerg Med. 2011. PMID: 21183085 No abstract available.

Cited by

Bhattacharya PK, Chakrabarti A, Sinha S, Pande R, Gupta S, Kumar AA, Mishra VK, Kumar S, Bhosale S, Reddy PK. Bhattacharya PK, et al. Indian J Crit Care Med. 2024 Aug;28(Suppl 2):S20-S41. doi: 10.5005/jp-journals-10071-24747. Epub 2024 Aug 10. Indian J Crit Care Med. 2024. PMID: 39234228 Free PMC article.

Fan X, Chen L, Chen M, Zhang N, Chang H, He M, Shen Z, Zhang L, Ding H, Xie Y, Huang Y, Ke W, Xiao M, Zang X, Xu H, Fang W, Li S, Cao C, Xu Y, Shan S, Wu W, Chen C, Xue X, Wang L. Fan X, et al. Innovation (Camb). 2024 Jul 31;5(5):100681. doi: 10.1016/j.xinn.2024.100681. eCollection 2024 Sep 9. Innovation (Camb). 2024. PMID: 39228856 Free PMC article.

He X, Yang X, Qin L, Zhang Q, Ji X, Tang W, Zhan Y, Zhang Y. He X, et al. Immunol Res. 2024 Sep 3. doi: 10.1007/s12026-024-09532-2. Online ahead of print. Immunol Res. 2024. PMID: 39223434

Kitaya S, Nakano M, Katori Y, Yasuda S, Kanamori H. Kitaya S, et al. Microorganisms. 2024 Aug 8;12(8):1619. doi: 10.3390/microorganisms12081619. Microorganisms. 2024. PMID: 39203461 Free PMC article. Review.

Takoutsing BD, Ooi SZY, Egu C, Gillespie CS, Dalle DU, Erhabor J, Ciuculete AC, Kesici Ö, Awad AK, Dokponou YCH, Khan M, Ikwuegbuenyi CA, Dada OE, Bandyopadhyay S, Bankole NDA. Takoutsing BD, et al. BMC Infect Dis. 2024 Aug 6;24(1):789. doi: 10.1186/s12879-024-09694-2. BMC Infect Dis. 2024. PMID: 39107727 Free PMC article. Review.

References

1. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America Clin Infect Dis. 2000;30:710–718. - PubMed
1. Shoham S, Cover C, Donegan N, et al. Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis. 2005;40:477–479. - PubMed
1. Dromer F, Bernede-Bauduin C, Guillemot D, et al. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE. 2008;3:e2870. - PMC - PubMed
1. Kwon-Chung KJ, Boekhout T, Fell JW, et al. Proposal to conserve the name Cryptococcus gattii against C. hondurianus and C. bacilli-sporus (Basidiomycota, Hymenomycetes, Tremellomycetidae) Taxon. 2002;51:804–806.
1. Kidd SE, Hagen F, Tscharke RL, et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada) Proc Natl Acad Sci U S A. 2004;101:17258–17263. - PMC - PubMed

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america

Conflict of interest statement

Comment in

Similar articles

Cited by

References